Loading…
Loading…
BIDU does not currently pay a dividend.
Sell-side consensus EPS, revenue estimates, YoY growth, forward P/E, and per-year analyst coverage — for any covered stock.
Click below to see what's inside, then upgrade to unlock for this and 80,000+ other tickers.
A year-by-year projected price path from the sell-side EPS consensus, with an editable target P/E and the implied annual return from today's price.
Click below to see what's inside, then upgrade to unlock for BIDU and 80,000+ other tickers.
See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.
Click below to see what's inside, then upgrade to unlock for BIDU and 80,000+ other tickers.
See exactly how BIDU's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for BIDU and 80,000+ other tickers.
Baidu, Inc. is a prominent Chinese technology company that offers various internet-based services, primarily focusing on digital marketing and cloud computing, all delivered through its extensive online platform within the People's Republic of China. The company's operations are segmented into two main divisions: Baidu Core and iQIYI. The Baidu Core segment encompasses a wide array of services, including online marketing derived from search queries and user feeds, comprehensive cloud solutions, and innovative products and services developed from its artificial intelligence initiatives. This…
The "Google of China" never quite fulfilled its promise to investors.
BEIJING, July 22, 2026 /PRNewswire/ -- Baidu, Inc. ("Baidu" or the "Company") (Nasdaq: BIDU; HKEX: 9888 (HKD Counter) and 89888 (RMB Counter)), a leading AI company with strong Internet foundation, today provides an update on the Company's proposed voluntary conversion of its secondary listing status on The Main Board of The Stock Exchange of Hong Kong Limited (the "Hong Kong Stock Exchange") to dual-primary listing (the "Primary Conversion"). Application for Conversion to Dual-Primary Listing.
San Diego-based Axiom Biosciences plans to seek a primary listing in Hong Kong in 2027, followed by a secondary U.S. listing in 2029. Global biotech firms are increasingly eyeing Hong Kong for its growing investor base and its proximity to Chinese pharmaceutical partners, which could help speed up trials and lower costs.
Baidu Inc. (BIDU) concluded the recent trading session at $108.22, signifying a -1.45% move from its prior day's close.
For nearly two years, the knock on Apple (NASDAQ:AAPL | AAPL Price Prediction) was that it had fallen behind in artificial intelligence.